Price
No data yet.
Social Signal Score
Revenue
$49.13MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Butler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 194
- Beta
- 0.23
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -5.68
Financials
Revenue
$49.13M+3100.5%Net Income
$-8.91MEBITDA
$-4.85MFree Cash Flow
$2.45MEPS (diluted)
$-0.03Shares Outstanding (diluted)
269.60M+611.4%Operating Expenses
$42.23MCash & Debt
$155.55MReturn of Capital
$0.00Revenue by Segment (annual)
$9.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $236.20M | $-5.34M | $-0.02 |
| 2024 | $160.18M | $-69.41M | $-0.33 |
| 2023 | $194.62M | $-51.92M | $-0.28 |
| 2022 | $292.48M | $-94.23M | $-0.58 |
| 2021 | $211.65M | $-282.02M | $-1.48 |
| 2020 | $294.64M | $-384.84M | $-2.53 |
| 2019 | $335.00M | $-279.66M | $-2.36 |
| 2018 | $207.74M | $-171.90M | $-1.47 |
| 2017 | $177.98M | $-76.91M | $-1.77 |
| 2016 | $1.53M | $-135.75M | $-3.60 |
| 2015 | $0.00 | $-60.72M | $-2.29 |
| 2014 | $0.00 | $-37.03M | $-2.40 |
| 2013 | $0.00 | $-13.17M | $-0.68 |
| 2012 | $0.00 | $-8.20M | $-0.81 |
Valuation
AKBAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsglobenewswire.com·5h ago·Neutral
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P.
View source ↗
Earnings
Mon, Nov 9(in 2 months)
Consensus estimate $-0.03 per share
Typical surprise +52.4% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.02 vs $-0.04beat
- Thu, May 7$-0.03 vs $-0.01miss
- Thu, Feb 26$-0.05 vs $-0.03miss
- Mon, Nov 10$0.00 vs $-0.06beat
- Thu, Aug 7$0.00 vs $-0.02beat
- Thu, May 8$0.03 vs $-0.03beat
Estimates and results for AKBA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AKBA officers and directors.
- Bought
- $87k
- Sold
- $1.9m
1 trade
27 trades
- Ostrowski Eriksold
- Butler John P.bought
- Malabre Richard Csold
- Malabre Richard Csold
- Grund Nicholassold
- Grund Nicholassold
- Burke Steven Keithsold
- Burke Steven Keithsold
72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.